ReviewMycology2025
Research advances and public health strategies in China on WHO priority fungal pathogens.
Review in Mycology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Antifungal Susceptibility andMicroorganisms · 2026Article
- Asian consensus on diagnostic algorithm for invasive pulmonary fungal diseases in high-burden settings.Journal of translational internal medicine · 2026Article
- Review
- Strain-Dependent Protective Innate Immunity AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Persistence and spread of fluconazole-resistantMicrobial genomics · 2026Article
- Novel Genetic Diversity and Geographic Structures ofMicroorganisms · 2026Article
- Genetic diversity and antifungal susceptibility among ecological niche populations of Aspergillus flavus in Yaoundé, Cameroon.PloS one · 2026Article
- Tackling a global threat: a clinical scenario-based framework for preventing and managingFrontiers in cellular and infection microbiology · 2026Review
- Genomic evidence for a-α heterothallic and α-α unisexual mating and recombination in an environmental Cryptococcus deneoformans population.PLoS genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal pathogens pose significant and increasing threats to public health. Each year, over a billion people are infected by fungal pathogens, directly contributing to millions of deaths. To overcome the challenge of fungal threat, in 2022, World Health Organization (WHO) issued a Fungal Priority Pathogens List (FPPL) aimed at strengthening international response, promoting research, and enhancing policy intervention development. Over the past four decades, China has made tremendous progress in advancing our knowledge of fungal infections. Here, we review research trends and recent progress in China on fungal pathogens on the WHO FPPL, with an emphasis on four critical pathogens:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.